News
-
-
COMMUNIQUÉ DE PRESSE
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the launch of the Phase 2 OBA Clinical Trial in Obesity in 2025. The study aims to evaluate the efficacy of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in obese patients -
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Biophytis announces the settlement and delivery of its €2.6 million private placement
Biophytis announces the settlement and delivery of its €2.6 million private placement. New shares admitted for trading on Euronext Growth. Maxim Group LLC and Invest Securities involved in the transaction -
COMMUNIQUÉ RÉGLEMENTÉ
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions d'euros
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions d'euros. Les actions seront cotées sur Euronext Growth. Maxim Group LLC et Invest Securities ont agi en tant qu'agents de placement -
-
-
-
